Buscar
Mostrando ítems 31-40 de 65
Artículo
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
(Elsevier, 2022)
Background: Breast cancer is the most common malignancy and the second leading cause of cancer-related mortality in Spanish women. Ribociclib in combination with endocrine therapy (ET) has shown superiority in prolonging ...
Artículo
Sam68 Mediates the Activation of Insulin and Leptin Signalling in Breast Cancer Cells
(Public Library Science, 2016)
Obesity is a well-known risk factor for breast cancer development in postmenopausal women. High insulin and leptin levels seem to have a role modulating the growth of these tumours. Sam68 is an RNA-binding protein with ...
Artículo
Low levels of granulocytic myeloid-derived suppressor cells may be a good marker of survival in the follow-up of patients with severe COVID-19
(Frontiers Media S.A., 2022)
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a disease (coronavirus disease 2019, COVID-19) that may develop into a systemic disease with immunosuppression and death in its severe ...
Artículo
The tumour microenvironment as an integrated framework to understand cancer biology
(Elsevier Ireland Ltd, 2019)
Cancer cells all share the feature of being immersed in a complex environment with altered cell-cell/cell-ex tracellular element communication, physicochemical information, and tissue functions. The so-called tumour mic ...
Artículo
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
(Nature Research, 2021-12-01)
Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations. Previous preclinical studies suggested that an ...
Artículo
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
(BMJ Publishing Group, 2021-08-21)
Background Several therapeutic options are now available in the adjuvant melanoma setting, mandating an understanding of their benefit‒risk profiles in order to make informed treatment decisions. Herein we characterize ...
Artículo
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma
(Nature publishing group, 2018)
Background: In the coBRIM study, cobimetinib plus vemurafenib (C þ V) significantly improved survival outcomes vs placebo and vemurafenib (P þ V) in patients with advanced/metastatic BRAFV600-mutated melanoma. An analysis ...
Artículo
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis
(Oxford University Press, 2024)
Background: Tebentafusp demonstrated a superior overall survival (OS) benefit [hazard ratio (HR) 0.51] compared to investigator’s choice (82% pembrolizumab) in a randomized, phase III trial (IMCgp100-202; N ¼ 378) in ...
Artículo
SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma
(Springer, 2015)
Follicular non-Hodgkin’s lymphoma (FL) is a nodal B lymphoid malignancy that originates from the germinal center of a lymph node. FL is the second most frequent lymphoma subtype. The course of the disease is usually ...
Artículo
Genes involved in immune reinduction may constitute biomarkers of response for metastatic melanoma patients treated with targeted therapy
(MDPI, 2022)
Targeted therapy in metastatic melanoma often achieves a major tumour regression response and significant long-term survival via the release of antigens that reinduce immunocompetence. The biomarkers thus activated may ...